Vaccinations have been completed and Valneva expects VALOR trial outcomes to be announced in the first half of 2026, followed by regulatory submissions as planned. Pfizer aims to submit a Biologics ...
Pfizer (PFE) has reportedly decided to sell its entire remaining stake in BioNTech (BNTX), showing a lack of confidence in ...
The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...
Texas's top prosecutor on Wednesday announced the state had reached a $41.5 million settlement with US drugmakers Pfizer and ...
The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.
10h
New mRNA flu vaccine far more effective than existing jabs, but has some limitations, study finds
A newly developed mRNA-based flu vaccine is almost 35 per cent more effective against the most common form of influenza, ...
Discover why Pfizer stock may be set for a bull run by 2026 with key wins, strong Q3 earnings, and growth drivers.
MyChesCo on MSN
Arbutus Reports Major Advances in HBV Candidate as Litigation Against Moderna, Pfizer Builds Toward Trial
WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) reported third quarter 2025 financial results and released new ...
A wave of lawsuits with novel strategies show that the search for Covid vengeance — and jury awards — has gained force under ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback